NSB — Neuroscientific Biopharmaceuticals Share Price
0.000.00%
Last trade - 00:00- AU$7.66m
- AU$4.33m
- AU$5.06m
- 75
- 65
- 23
- 56
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.01 | ||
| Price to Tang. Book | 2.27 | ||
| Price to Free Cashflow | 731.3 | ||
| Price to Sales | 1.95 | ||
| EV to EBITDA | 5.12 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 20.35% | ||
| Return on Equity | 23.29% | ||
| Operating Margin | 19.7% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.12 | 0.08 | 1.05 | 0.07 | 5.06 | n/a | n/a | 179.97% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NeuroScientific Biopharmaceuticals Limited is an Australia-based company that is engaged in developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The Company’s product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer’s disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn), which have demonstrated similar therapeutic potential as EmtinB. EmtinB is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body’s innate immune response to cell injury.
Directors
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 14th, 2002
- Public Since
- July 27th, 2018
- No. of Shareholders
- 1,407
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 144,604,870
- Address
- Suite 5, 85 Forrest St, Cottesloe, NEDLANDS, 6011
- Web
- https://neuroscientific.com/
- Phone
- +61 863821800
- Auditors
- Nexia Perth Audit Services Pty Ltd
Upcoming Events for NSB
Similar to NSB
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Neuroscientific Biopharmaceuticals share price?
As of Today at 19:15 UTC, shares in Neuroscientific Biopharmaceuticals are trading at AU$0.05. This share price information is delayed by 15 minutes.
How has the Neuroscientific Biopharmaceuticals share price performed this year?
Shares in Neuroscientific Biopharmaceuticals last closed at AU$0.05 and the price had moved by -29.33% over the past 365 days. In terms of relative price strength the Neuroscientific Biopharmaceuticals share price has underperformed the ASX All Ordinaries Index by -32.41% over the past year.
What are the analyst and broker recommendations for Neuroscientific Biopharmaceuticals?
There is no consensus recommendation for this security.
What is the Neuroscientific Biopharmaceuticals dividend yield?
Neuroscientific Biopharmaceuticals does not currently pay a dividend.
Does Neuroscientific Biopharmaceuticals pay a dividend?
Neuroscientific Biopharmaceuticals does not currently pay a dividend.
When does Neuroscientific Biopharmaceuticals next pay dividends?
Neuroscientific Biopharmaceuticals does not currently pay a dividend.
How do I buy Neuroscientific Biopharmaceuticals shares?
To buy shares in Neuroscientific Biopharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Neuroscientific Biopharmaceuticals?
As of the previous close price of AU$0.05, shares in Neuroscientific Biopharmaceuticals had a market capitalisation of AU$7.66m.
Where are Neuroscientific Biopharmaceuticals shares listed?
Here are the trading details for Neuroscientific Biopharmaceuticals:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: NSB
What kind of share is Neuroscientific Biopharmaceuticals?
Based on an overall assessment of its quality, value and momentum Neuroscientific Biopharmaceuticals is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Neuroscientific Biopharmaceuticals share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Neuroscientific Biopharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neuroscientific Biopharmaceuticals. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -32.61%.
As of the last closing price of AU$0.05, shares in Neuroscientific Biopharmaceuticals were trading -23.16% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Neuroscientific Biopharmaceuticals PE Ratio?
The Neuroscientific Biopharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Neuroscientific Biopharmaceuticals?
Neuroscientific Biopharmaceuticals' management team is headed by:
- Paul Rennie - NEC
- Matthew Liddelow - CEO
- Abby Macnish Niven - CFO
- Anton Uvarov - EDR
- Stephen Quantrill - NED